I like smarter guys than me to do the earlier heavy lifting. So I look for good successful investors who are also buying the stock. When it comes to DNDN that’s easy. According to recent filing there are at least 4 super billionaire investors …
Shares of Dendreon are off over 2% today despite an overall flat market. And down 12% in the past week despite the S&P being down about 0.4%. But even more importantly, shares of DNDN, currently at 34 and change are off 23 points from …
That move prompted at least six brokerages to cut their rating on Dendreon s stock. The company has pointed to reimbursement concerns and delayed physician adoption as the primary reasons why Provenge s sales growth has …
NEW YORK (Reuters) - A lightening fast sell-off of shares of biotech company Dendreon last April is drawing scrutiny from U.S. securities regulators and the independent monitor assigned to keep tabs on those regulators, said people …
Dendreon Corporation (NASDAQ ... We checked around to find out if one could borrow DNDN stock. We are told there is a -9.95% rebate on anything above 200,000 shares. Is there hope? Last quarter, DNDN announced more data analysis …
J.P. Morgan (NYSE: JPM) has a $46 price target on the shares. During the last 52 weeks, Dendreon's stock has traded from a low of $2.55 to a high of $33.85. There are few signs that the momentum in this name will not continue. If their …
Shares of the drugmaker Dendreon are plummeting in trading, a day after the company announced a restructuring that includes closing a Morris County manufacturing plant. The Seattle-based company saw its stock slide more than 22 …
The volatility of Dendreon's stock provides a fascinating insight into the allure of a new treatment modality, the bungles of the Provenge trials and the steely determination of the company to bring its first ever product to market. Dendreon's …
Shares dipped 9.34 percent to $29.01 in early market trading. Dendreon Corporation (NASDAQ:DNDN): The biotech stock has been heavily shorted for the past two years. The company’s prostate cancer drug, Provenge, faced reimbursement …
An analyst apologized to clients late Wednesday for his calls on troubled biotechnology company Dendreon Corp., as he moved his rating on the shares to hold from buy in the wake of the company lowering sales estimates for the coming …